Treatment of Stage II Thymoma with Pathologically Demonstrated Capsular Invasion
When thymoma has spread beyond the thymic capsule — confirmed on pathological examination — this defines Stage II disease and changes the treatment approach. Capsular invasion, even when resection appears complete, carries implications for local recurrence risk and guides adjuvant planning.
Clinical Scenario
Stage II thymoma with pathologically demonstrated capsular invasion of the thymus. Adjuvant radiation therapy after complete surgical excision has been considered a standard of care in this setting, despite the absence of prospective randomised trials.
Treatment Approach
Management centers on complete surgical removal of the thymoma. Depending on the status of the surgical margins, postoperative locoregional radiation therapy may be recommended — the full dosing strategy, fractionation scheme, and criteria determining whether radiation is indicated are detailed in the protocol →
References
- For patients with stage II thymomas with pathologically demonstrated capsular invasion, adjuvant radiation therapy after complete surgical excision has been considered a standard of care, despite the lack of prospective clinical trials.
- Most studies use 40 Gy to 70 Gy with a standard fractionation scheme (1.8–2.0 Gy per fraction).
- To avoid the potential morbidity and costs associated with thoracic radiation, PORT may be reserved for stage II patients when adjacent organs are within a few millimeters or involve the surgical margin (close or positive surgical margins), as determined by both pathological and intraoperative findings.
View source ↗